Similar studies for GEO DataSets (Select 200117523) - GEO DataSets

Select item 2001175231.

Targets of CDK12 on ZR-75-30 breast cancer cells (RNA-seq)

(Submitter supplied) RNA-sequencing analysis of CDK12 overexpressiong ZR-75-30 cell lines. Cyclin dependent kinase 12 (CDK12) is amplified in approximately 70-90% of HER2 amplified breast cancer. Results provide insight into the targets of CDK12 in HER2 positive breast cancer.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL16791
6 Samples

Download data: TXT

Series

Accession:: GSE117523

ID:: 200117523

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 2001192102.

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

(Submitter supplied) Amplification of chromosome 17q23 is a frequent genomic event that occurs in ~ 11% of human breast cancers. The 17q23 amplification is enriched in HER2+ breast cancers, which is significantly correlated with poor clinical outcomes. Previous studies have identified the oncogenic phosphatase WIP1 gene in the amplicon, which functions as a master inhibitor in DNA damage response. While the possibility of any other protein-coding oncogenes in the WIP1-containing 17q23 amplicon was ruled out, our analysis of human breast cancer genomics uncovered an oncogenic microRNA gene, MIR21, in a majority of the WIP1-containing amplicons. more...

Organism:: Mus musculus

Type:: Expression profiling by high throughput sequencing

Platform:: GPL21103
2 Samples

Download data: TXT

Series

Accession:: GSE119210

ID:: 200119210

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2000176303.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

(Submitter supplied) HER2 targeting with trastuzumab has changed the prognosis of breast cancer patients carrying amplification and/or overexpression of this oncogene. Despite this progress, however, resistance to trastuzumab occurs in the vast majority of patients. Newer anti-HER2 therapies, like the dual tyrosine-kinase inhibitor (TKI) lapatinib, show antitumor activity in a limited proportion of patients, indicating that HER2 can be still exploited as a target after trastuzumab failure. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL4133
2 Samples

Download data: TXT

Series

Accession:: GSE17630

ID:: 200017630

Select item 2001292544.

Pertubations of gene expresion by lapatinib or THZ1 in HER2 positive breast cancer cell lines.

(Submitter supplied) Gene expression profiling were examined by Human HT-12 v4.0 Expression BeadChip arrays in SKBR3 and BT474 cells treated with HER2 inhibitor lapatinib or CDK7 inhibitor THZ1.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL10558
18 Samples

Download data: IDAT

Series

Accession:: GSE129254

ID:: 200129254

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001278765.

Transcriptomic changes driven by oncogenic kinases

(Submitter supplied) Transcriptomic changes were compared by RNA-seq in human mammary epithelial cells (HMECs) with or without ectopic expression of oncogenic kinase HER2, PI3KCA(mut), or SHP(mut).

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL16791
12 Samples

Download data: TXT

Series

Accession:: GSE127876

ID:: 200127876

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 2001463806.

RNA sequencing of trastuzumab plus pertuzumab-refractory tumor in a mouse xenograft model

(Submitter supplied) We report RNA sequencing data of trastuzumab plus pertuzumab-refractory tumor in a mouse xenograft model.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
2 Samples

Download data: TXT

Series

Accession:: GSE146380

ID:: 200146380

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2001463077.

RNA sequencing of T-DM1-refractory tumor in a mouse xenograft model

(Submitter supplied) We report RNA sequencing data of T-DM1-refractory tumor in a mouse xenograft model.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
2 Samples

Download data: TXT

Series

Accession:: GSE146307

ID:: 200146307

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 2001024028.

Posttranscriptional upregulation of HER3 by HER2 mRNA induces Trastuzumab Resistance in breast cancer

(Submitter supplied) To explore HER2 3’-UTR-dependent transcriptional programs, we analyzed gene-expression profiles of T47D cells transfected with HER2 3’-UTR.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6480
2 Samples

Download data: TXT

Series

Accession:: GSE102402

ID:: 200102402

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000739009.

Gene Regulation by microRNA-16 forced expression in ErbB-2 positive murine breast cancer cells.

(Submitter supplied) miR-16 is a potent tumor suppressor in ErbB-2 positive breast cancer. The primary objetive of this study was to identify previously uncharacterized putative mRNA targets of miR-16 in ErbB-2 postitive breast cancer cells. To achieve our objective we studied the effects of exogenously expressed miR-16 on the gene expression profile of primary cultures of ErbB-2 positive murine breast cancer tumors. The C4HD tumor line displays high levels of estrogen receptor and progesterone receptor, overexpresses ErbB-2 and ErbB-3, exhibits low ErbB-4 levels, and lacks EGF-R expression.

Organism:: Mus musculus

Type:: Expression profiling by array

Platform:: GPL7202
6 Samples

Download data: TXT

Series

Accession:: GSE73900

ID:: 200073900

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20007134710.

HER2 signaling drives DNA anabolism and proliferation through SRC-3 phosphorylation and E2F1-regulated genes

(Submitter supplied) Approximately 20% of early-stage breast cancers display amplification or overexpression of the ErbB2/HER2 oncogene, conferring poor prognosis and resistance to endocrine therapy. Targeting HER2+ tumors with trastuzumab or the receptor tyrosine kinase (RTK) inhibitor lapatinib significantly improves survival, yet tumor resistance and progression of metastatic disease can develop over time. While the mechanisms of cytosolic HER2 signaling are well studied, nuclear signaling components and gene regulatory networks that bestow therapeutic resistance and limitless proliferative potential are incompletely understood. more...